Largest open-access resource of its kind will help prioritize which drugs to send to clinical studies
Scientists at Northwestern University have developed the largest open-access resource of its kind to help investigators shave off months of early-stage drug development time by allowing them to better understand diseases and find potential treatments.
Called SOAR (Spatial transcriptOmics Analysis Resource), the now-live platform is a one-stop shop that helps scientists explore how genes behave differently in various parts of the body, shows them how cells might be talking to each other and enables them to find new drug possibilities.
Spatial transcriptomics is a cutting-edge scientific method that helps investigators see which genes are active in different parts of a tissue, essentially giving scientists a bird’s eye view of cell interactions. SOAR is the first comprehensive spatial-transcriptomics resource designed expressly to accelerate drug-discovery pipelines.
“It’s too expensive and too time consuming to push thousands of potential drug candidates to the preclinical study and clinical trials,” said corresponding author Yuan Luo, PhD, chief AI officer at the Northwestern University Clinical and Translational Sciences (NUCATS) Institute and the Institute for Artificial Intelligence in Medicine. “We need to pick the right leads and then push them to downstream studies. This resource will help prioritize that.”
Research findings using the resource were published Science Advances. Several pharmaceutical companies are already looking to use SOAR in their research, Luo said.
Gives scientists a ‘molecular GPS’
SOAR aggregates data across 441 spatial transcriptomics datasets from 19 different spatial transcriptomics companies, allowing scientists to see detailed maps of gene activity across 3,461 tissue samples from 13 species (from humans to zebrafish) and 42 tissue types (e.g. breast, lung, brain, bowel, etc.).
By showing how genes are expressed — turned on or off — in different parts of a tissue and connecting that to how certain chemicals affect cells, this dataset acts like a “molecular GPS” — helping scientists zero in on the exact biological processes that could be targeted to treat diseases, Luo said.
Studying IBD to breast cancer
With disease, Luo said it’s often not the cell activity itself that is problematic, but rather where the cell activity is occurring.
“If immune cells are attacking normal cells in regular tissue, that’s really bad because that could give you inflammatory disease, like irritable bowel disease,” said Luo, who is also a professor of Preventive Medicine in the Division of Biostatistics and Informatics and and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “Or if the immune cells are not attacking cancer cells in a tumor microenvironment, that is really a bad thing because it lets the cancer grow. SOAR helps examine the variability and interactions to give researchers the understanding of what mechanism is going on so they can better understand what is underlining the disease.”
Peking University’s Zexian Zeng, PhD (a former trainee in the Luo lab and Northwestern alumnus) is a co-corresponding study author. Other Northwestern authors on the study include Yiming Li, PhD; Yanyi Ding; Saya Dennis; Meghan R. Hutch; Jiaqi Zhou; Yawei Li, PhD, research assistant professor of Preventive Medicine; Maalavika Pillai; Sanaz Ghotbaldini; Mario Alberto Garcia; Mia S. Broad; Chengsheng Mao, PhD, research assistant professorof Preventive Medicine; and Parambir S. Dulai, MD, associate professor of Medicine in the Division of Gastroenterology and Hepatology.
